Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Pablo Corral Shares Key Insights from the State-of-the-Art Review on PCSK9
Pablo Corral/LinkedIn
Nov 22, 2025, 17:16

Pablo Corral Shares Key Insights from the State-of-the-Art Review on PCSK9

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:

”The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease

Key Insights from the State-of-the-Art Review on PCSK9

A comprehensive review outlines how PCSK9 evolved from a genetic curiosity into a cornerstone of modern lipid-lowering therapy and ASCVD prevention:

  1. PCSK9 biology: By directing LDL receptors toward lysosomal degradation, PCSK9 is a critical regulator of circulating LDL-C levels and a direct determinant of atherogenic burden.
  2. Therapeutic impact: PCSK9 inhibition lowers LDL-C by 50–60% on top of statins, with consistent outcome benefits demonstrated in FOURIER and ODYSSEY.
  3. Long-term safety: Follow-up up to 8.4 years confirms safety even at very low LDL-C levels, with no signal for diabetes, neurocognitive events, or hemorrhagic stroke.
  4. Expanding modalities: Beyond monoclonal antibodies, new platforms include siRNA (inclisiran), adnectins (lerodalcibep), oral PCSK9 inhibitors (enlicitide, laroprovstat), and CRISPR base-editing — each aiming to improve potency, durability, and adherence.
  5. Clinical indications: Evidence supports use in secondary prevention, familial hypercholesterolemia, and selected high-risk primary prevention patients.
  6. Public health challenge: Despite strong evidence, <1% of eligible patients receive PCSK9 inhibitors due to cost and access barriers, underscoring the gap between science and implementation.”

Read the full article here.

Article: The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease

Authors: Alexander C. Razavi, Michael D. Shapiro

Pablo Corral Shares Key Insights from the State-of-the-Art Review on PCSK9

Stay updated on all scientific advances with Hemostasis Today.

Alexander C. Razavi ASCVD Atherosclerosis CRISPR enlicitide FOURIER Health Hematology Hemorrhagic Stroke Hemostasis Hemostasis Today inclisiran laroprovstat LDL lerodalcibep Medicine Michael D. Shapiro ODYSSEY Pablo Corral PCSK9 thrombosis
NewsFeed